Prospects for prophylactic hepatitis C vaccines based on virus-like particles
| Autor: | Philippe Roingeard, Elodie Beaumont |
|---|---|
| Přispěvatelé: | Roingeard, Philippe, Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856, Work on prophylactic hepatitis C vaccination strategies in our laboratory is currently supported by the Institut Mérieux, the Emergence program of the Agence Nationale pour la Recherche (ANR, France), the FEDER (Fonds Européens de Développements en Region - Région Centre, France) and the Cluster de Recherche en Infectiologie (Région Centre, France). |
| Rok vydání: | 2013 |
| Předmět: |
liver diseases
Hepacivirus Hepatitis C virus Immunology Drug Evaluation Preclinical viral hepatitis medicine.disease_cause immune response Virus virus-like particle 03 medical and health sciences 0302 clinical medicine MESH: Drug Discovery Virus-like particle MESH: Viral Vaccines [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Drug Discovery medicine Humans Immunology and Allergy MESH: Hepacivirus Vaccines Virus-Like Particle MESH: Vaccines Virus-Like Particle 030304 developmental biology MESH: Hepatitis C Pharmacology 0303 health sciences MESH: Humans biology business.industry Viral Vaccine Viral Vaccines Hepatitis C medicine.disease biology.organism_classification Virology 3. Good health Vaccination [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Commentary MESH: Drug Evaluation Preclinical 030211 gastroenterology & hepatology preventive vaccination business Viral hepatitis |
| Zdroj: | Human Vaccines & Immunotherapeutics Human Vaccines & Immunotherapeutics, Taylor & Francis, 2013, 9 (5), pp.1112-8. ⟨10.4161/hv.23900⟩ |
| ISSN: | 2164-554X 2164-5515 |
| DOI: | 10.4161/hv.23900 |
| Popis: | International audience; Given the global prevalence and long-term complications of chronic hepatitis C virus (HCV) infection, HCV constitutes one of the greatest challenges to human health of this decade. Considerable efforts have focused on the development of new effective treatments, but about three to four million individuals become infected each year, adding to the world reservoir of HCV infection. The development of a prophylactic vaccine against hepatitis C virus has thus become an important medical priority. Only a few vaccine candidates have progressed to the clinical phase, and published data on both the efficacy and safety of these vaccines are limited, due to many scientific, logistic and bioethic challenges. Fortunately, new innovative vaccine formulations, modes of vaccination and delivery technologies have been developed in recent years. Several preclinical trials of virus-like particle (VLP)-based vaccination strategies are currently underway and have already generated very promising results. In this commentary, we consider the current state of prophylactic HCV vaccines, the hurdles to be overcome in the future and the various VLP-based vaccination approaches currently being developed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|